SVA [SINOVAC BIOTECH] 6-K: SINOVAC RECEIVES REVISED APPROVALS FOR PANFLU Extension of
[SINOVAC RECEIVES REVISED APPROVALS FOR PANFLU Extension of Eligible Age Group Enables Sinovac to Cover Larger Part of Population Increased Panflu Dosage to 1mL per Vial Expands Filling and Packaging Capacity BEIJING, June 29 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that it has received a revised Drug] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]